{"id":"placebo-to-match-oseltamivir-phosphate","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The active form of oseltamivir phosphate binds to the neuraminidase protein on the surface of influenza viruses, preventing the release of new viral particles from infected cells. This action helps to reduce the spread of the virus within the body and alleviate symptoms of influenza.","oneSentence":"Oseltamivir phosphate is a prodrug that is metabolized into its active form, which is a selective inhibitor of the influenza virus neuraminidase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:51.188Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment and prophylaxis of influenza A and B in patients 1 year and older"}]},"trialDetails":[{"nctId":"NCT07095257","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza","status":"RECRUITING","sponsor":"Nanjing Zenshine Pharmaceuticals","startDate":"2025-10-13","conditions":"Respiratory Viral Infection","enrollment":168},{"nctId":"NCT04982913","phase":"PHASE1","title":"Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-08-24","conditions":"Influenza","enrollment":118},{"nctId":"NCT02469298","phase":"PHASE2","title":"Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-01","conditions":"Virus Diseases","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo To Match Oseltamivir Phosphate","genericName":"Placebo To Match Oseltamivir Phosphate","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oseltamivir phosphate is a prodrug that is metabolized into its active form, which is a selective inhibitor of the influenza virus neuraminidase. Used for Treatment and prophylaxis of influenza A and B in patients 1 year and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}